Clinical Data ADA: AZ reveals oral GLP-1 data in obesity, diabetes PharmaphorumAstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.Metabolic & GLP-1Read full story pharminent June 9, 2026 (Last updated: June 11, 2026) Pharmaphorum AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer’s Hympavzi secures FDA expanded indications for haemophiliaNext: ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
